Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ascending-dose study of LEO 158968 in healthy subjects
NL-OMON53439Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LEO 158968 in Inflammatory Disorders (15 cohorts), sponsored by LEO Pharma. Primary endpoint: Safety and tolerability. Started Jan 2023; status: completed.
02
Drugs
LEO 158968
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NL-OMON53439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53439.